Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
- Conditions
- STAT1 Gain-of-Function Disease
- Registration Number
- NCT05561985
- Lead Sponsor
- Incyte Corporation
- Brief Summary
Expanded access use of Itacitinib to treat a single patient with aplastic anemia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Itacitinib's efficacy in STAT1 gain-of-function (GOF) disease and aplastic anemia?
How does Itacitinib compare to standard-of-care therapies for STAT1 GOF-related aplastic anemia in clinical outcomes?
Which biomarkers correlate with Itacitinib response in patients with STAT1 GOF disease and bone marrow failure?
What adverse events are associated with Itacitinib in STAT1 GOF disease, and how are they managed in expanded access protocols?
Are there combination therapies or alternative JAK inhibitors being explored for STAT1 GOF disease beyond Incyte's Itacitinib?